Furthermore, the oncofetal protein ROR1 was coexpressed with BCL-2 in multiple tumors, including SCLC, and functional experiments revealed that the ROR1 inhibitor (KAN0441571C) in combination with venetoclax produced synergistic effects in SCLC models [145]. This evidence concerns the gene ROR1 and small cell lung carcinoma.